Showing 2271-2280 of 5789 results for "".
- FDA Green-lights Casio’s DZ-D100 Dermocamera and the DZ-S50 Scopehttps://practicaldermatology.com/news/fda-green-lights-casios-dz-d100-dermocamera-and-the-dz-s50-scope/2461076/The U.S. Food and Drug Administration (FDA) has cleared Casio’s
- GW Dermatology, La Roche-Posay Establish GW Skin Cancer Research Acceleration Fundhttps://practicaldermatology.com/news/gw-dermatology-la-roche-posay-establish-gw-skin-cancer-research-acceleration-fund/2461074/The Department of Dermatology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) has partnered with La Roche-Posay to establish the La Roche-Posay Skin Cancer Research Acceleration Fund at GW. The $50,000 gift will be used to support the growth
- Solta Medical Files for IPOhttps://practicaldermatology.com/news/solta-medical-files-for-ipo/2461072/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training
- National Foundation for Cancer Research Taps NYC Dermatologist for Board Seathttps://practicaldermatology.com/news/national-foundation-for-cancer-research-taps-dermatologist-for-board-seat/2461065/The National Foundation for Cancer Research (NFCR) has announced that New York dermatologist Dr. Karen Burke and two others will be joining the board. NFCR was founded in 1973 to support cancer research and public education relating to the prevention, early diagnosis, better treatments
- Dupixent Update: Medication Shows Promise in Five Inflammatory Diseaseshttps://practicaldermatology.com/news/dupixent-update-medication-shows-promise-in-five-inflammatory-diseases/2461063/Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive result
- Merz Aesthetics Launches Radiesse (+) as First and Only Aesthetic Injectable to Improve Moderate to Severe Loss of Jawline Contourhttps://practicaldermatology.com/news/merz-aesthetics-launches-radiesse-as-first-and-only-aesthetic-injectable-to-improve-moderate-to-severe-loss-of-jawline-contour/2461062/Merz Aesthetics is launching Radiesse (+) Lidocaine for jawline contouring in adults over the age of 21. Radiesse (+) is the first and only U.S. Food and Drug Administration (FDA)-approved injectable treatment for jawline contour improvement. The FDA approved the supplemental
- FDA Accepts Label Update for Suneva’s Plasma IQhttps://practicaldermatology.com/news/fda-accepts-label-update-for-sunevas-plasma-iq/2461061/Plasma IQ label, including the removal of the product's eye contraindication. The removal of this specific contraindication was due in part to a compilation of literature provided to the FDA showing the safety and efficacy of the ablative device on skin tissue, particular
- Morgan Dermatology to Expand with Financing from TD Bankhttps://practicaldermatology.com/news/morgan-dermatology-to-expand-with-financing-from-td-bank/2461058/Morgan Dermatology is expanding, thanks to a $1.38 million term loan and $5.26 million Commercial Real Estate Mortgage (CREM) from
- Light Therapy Fast-tracks Healing of Skin Damage from Brachytherapyhttps://practicaldermatology.com/news/light-therapy-fast-tracks-healing-of-skin-damage-from-brachytherapy/2461055/Light therapy may accelerate the healing of skin damage from radiation therapy by up to 50 percent, according to a recent University at Buffalo-led study. Photobiomodulation – a form of low-dose light therapy –lowered the severity of skin damage from radionecrosis, reduced i